TrippBio, a biotechnology company, is producing a patent-pending repurposed FDA-approved drug called TD213 intended for the treatment of viral infections, initially targeting COVID-19, it was reported on Monday.
TD213 is administered orally twice daily and works by halting the SARS-CoV-2 virus and the associated acute inflammatory response to the infection.
The firm has revealed positive interim data from the investigator-initiated study to evaluate the efficacy of the product in treating patients with confirmed mild-moderate COVD-19.
Dr Moti N. Ramgopal of Midway Immunology and Research Center conducted the study. Outpatients who tested positive using a validated SARS-CoV-2 RNA COVID-19 test were administered the product twice daily for 14 days and will be followed until day 28.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins